D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]Methyl]-4-Methylphenyl]-, tetraacetate, (1S)- (9CI) Chemical Properties

Melting point:

160-170 °C

Boiling point:

658.3±55.0 °C(Predicted)

Density 

1.32±0.1 g/cm3(Predicted)

vapor pressure 

0Pa at 20℃

solubility 

soluble in Chloroform, Ethyl Acetate, Methanol

form 

Solid

color 

White

LogP

5.5 at 20℃

D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]Methyl]-4-Methylphenyl]-, tetraacetate, (1S)- (9CI) Usage And Synthesis

Uses

The title compound is an intermediate in the synthesis of Canagliflozin which is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity.

Flammability and Explosibility

Not classified

D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]Methyl]-4-Methylphenyl]-, tetraacetate, (1S)- (9CI)(866607-35-4)Related Product Information

• Acridine
• Ethanol
• 1,2,3,4-Butanetetracarboxylic acid
• Canagliflozin Impurity 18 (Mixture of Diastereomers)
• Canagliflozin Impurity 10
• Canagliflozin Impurity 17
• 5-Bromo-2-methylbenzoic acid
• 2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene
• (5-broMo-2-Methylphenyl)(5-(4-fluorophenyl)thiophen-2-yl)Methanone
• 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene
• 5-Bromo-2-methylbenzoyl chloride
• 5-Iodo-2-methylbenzoic acid
• Canagliflozin heMihydrate
• 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone
• LIPOPHILIC SEPHADEX
• 2-(4-Fluorophenyl)-thiophene
• BCP19353
• Canagliflozin